2[2]Hsiang YH,liu LF.Identification of mammalian DNAtopoisomerase I as an intracellular target of the anticancer drug camptothecin J[J].Cancer Res,1988,45(7) :1722-1726.
5[5]Hanna N,Sweeney C,Fife K,et al.Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors[J].Am J Clin Oncol,2003,26(2):200-202.
6[6]Gwyther S,Bolis G,Gore M,et al.Experience with independent radiological review during a topotecan trial in ovarian cancer[J].Ann Oncol,1997,8:463-468.
8[8]Hochster H,Speyer J,Wadler S,et al.Phase Ⅱ study of topotecan(TPT) 21-day infusion in platinum-treated ovarian cancer:A highly active regimen(a NYGOG study)[J].Proc Am Soc Clin Oncol,1996,15:285-287.
9[9]Creemers GJ,Bolis G,Gore M,et al.Scarfone G Topotecan,an active drug in the second-line treatment of epithelial ovarian cancer:results of a large European phase Ⅱ study[J].J Clin Oncol,1996,14:3056-3061.
10[10]Brown JV,Peters WA,Rettenmaier MA,et al.Three-consecutive-day topotecan is an active regimen for recurrent epithelialovarian cancer[J].Gynecol Oncol,2003,88(2):136-140.
1A. Kathleen McClendon. DNA topoisomerase Ⅱ[J]. genotoxicity, and cancer Mutation Research 2007, 623: 83- 97.
2Lok RB. Anti-cancer Drug Design, 1987 (2)151-164.
3Cheng C. Conservation of structure and mechanism between eukaryotic topoisomerase Ⅰ and site-specific recombinases [ J ]. Cell, 1998,92 (6) : 841-850.
4Redinbo MR. Crystal structures of human topoisomerase Ⅰ in covalent and noncovalent complexes with DNA [J ]. Science, 1998, 279 (5356): 1504-1513.
5Stewart L. A model for the mechanism of human topoisomerase Ⅰ [J]. Science , 1998, 279(5356): 1534-1541.
6Redinbo MR. Novel Insights into Catalytic Mechanism from a Crystal Structure of Human Topoisomerase Ⅰ in Complex with DNA [ J ] . Biochemistry, 2000, 39 (23) : 6832-6840.
7Leteurtre F. Saintopin, a dual inhibitor of DNA topoisomerases Ⅰ and Ⅱ, as a probe for drug-enzyme interactions [J]. J Biol Chem,1994, 269(46): 28702-28707.
8Janin YL. Synthesis and evaluation of new 6-amino-substituted benzo[c ]phenanthridine derivatives [J]. J Med Chem, 1993, 36(23): 3686-3692.
9Von-Hoff DD. Preclinical and phase Ⅰ trials of topoisomerase Ⅰ inhibitors [J]. Cancer Chemother Pharmacol, 1994, 34(Suppl): S41-S45.
10Utsugi T. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases Ⅰ and Ⅱ[J]. Jpn J Cancer Res, 1997, 88(10): 992-1002.
